Profiling and targeting of cellular bioenergetics: Inhibition of pancreatic cancer cell proliferation

G. Cheng, J. Zielonka, D. McAllister, S. Tsai, M. B. Dwinell, B. Kalyanaraman

Research output: Contribution to journalArticle

Abstract

Background:Targeting both mitochondrial bioenergetics and glycolysis pathway is an effective way to inhibit proliferation of tumour cells, including those that are resistant to conventional chemotherapeutics.Methods:In this study, using the Seahorse 96-well Extracellular Flux Analyzer, we mapped the two intrinsic cellular bioenergetic parameters, oxygen consumption rate and proton production rate in six different pancreatic cancer cell lines and determined their differential sensitivity to mitochondrial and glycolytic inhibitors.Results:There exists a very close relationship among intracellular bioenergetic parameters, depletion of ATP and anti-proliferative effects (inhibition of colony-forming ability) in pancreatic cancer cells derived from different genetic backgrounds treated with the glycolytic inhibitor, 2-deoxyglucose (2-DG). The most glycolytic pancreatic cancer cell line was exquisitely sensitive to 2-DG, whereas the least glycolytic pancreatic cancer cell was resistant to 2-DG. However, when combined with metformin, inhibitor of mitochondrial respiration and activator of AMP-activated protein kinase, 2-DG synergistically enhanced ATP depletion and inhibited cell proliferation even in poorly glycolytic, 2-DG-resistant pancreatic cancer cell line. Furthermore, treatment with conventional chemotherapeutic drugs (e.g., gemcitabine and doxorubicin) or COX-2 inhibitor, celecoxib, sensitised the cells to 2-DG treatment.Conclusions:Detailed profiling of cellular bioenergetics can provide new insight into the design of therapeutic strategies for inhibiting pancreatic cancer cell metabolism and proliferation.

Original languageEnglish (US)
Pages (from-to)85-93
Number of pages9
JournalBritish Journal of Cancer
Volume111
Issue number1
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Deoxyglucose
Pancreatic Neoplasms
Energy Metabolism
Cell Proliferation
Celecoxib
gemcitabine
Cell Line
Adenosine Triphosphate
Smegmamorpha
AMP-Activated Protein Kinases
Cyclooxygenase 2 Inhibitors
Metformin
Glycolysis
Oxygen Consumption
Doxorubicin
Protons
Respiration
Pharmaceutical Preparations
Neoplasms

Keywords

  • 2-deoxyglucose
  • bioenergetics
  • cell proliferation
  • glycolysis
  • metformin
  • mitochondrial respiration
  • pancreatic cancer
  • targeted therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cheng, G., Zielonka, J., McAllister, D., Tsai, S., Dwinell, M. B., & Kalyanaraman, B. (2014). Profiling and targeting of cellular bioenergetics: Inhibition of pancreatic cancer cell proliferation. British Journal of Cancer, 111(1), 85-93. https://doi.org/10.1038/bjc.2014.272

Profiling and targeting of cellular bioenergetics : Inhibition of pancreatic cancer cell proliferation. / Cheng, G.; Zielonka, J.; McAllister, D.; Tsai, S.; Dwinell, M. B.; Kalyanaraman, B.

In: British Journal of Cancer, Vol. 111, No. 1, 2014, p. 85-93.

Research output: Contribution to journalArticle

Cheng, G, Zielonka, J, McAllister, D, Tsai, S, Dwinell, MB & Kalyanaraman, B 2014, 'Profiling and targeting of cellular bioenergetics: Inhibition of pancreatic cancer cell proliferation', British Journal of Cancer, vol. 111, no. 1, pp. 85-93. https://doi.org/10.1038/bjc.2014.272
Cheng, G. ; Zielonka, J. ; McAllister, D. ; Tsai, S. ; Dwinell, M. B. ; Kalyanaraman, B. / Profiling and targeting of cellular bioenergetics : Inhibition of pancreatic cancer cell proliferation. In: British Journal of Cancer. 2014 ; Vol. 111, No. 1. pp. 85-93.
@article{7d1aba88bd5e4b6496386fc32abbed1d,
title = "Profiling and targeting of cellular bioenergetics: Inhibition of pancreatic cancer cell proliferation",
abstract = "Background:Targeting both mitochondrial bioenergetics and glycolysis pathway is an effective way to inhibit proliferation of tumour cells, including those that are resistant to conventional chemotherapeutics.Methods:In this study, using the Seahorse 96-well Extracellular Flux Analyzer, we mapped the two intrinsic cellular bioenergetic parameters, oxygen consumption rate and proton production rate in six different pancreatic cancer cell lines and determined their differential sensitivity to mitochondrial and glycolytic inhibitors.Results:There exists a very close relationship among intracellular bioenergetic parameters, depletion of ATP and anti-proliferative effects (inhibition of colony-forming ability) in pancreatic cancer cells derived from different genetic backgrounds treated with the glycolytic inhibitor, 2-deoxyglucose (2-DG). The most glycolytic pancreatic cancer cell line was exquisitely sensitive to 2-DG, whereas the least glycolytic pancreatic cancer cell was resistant to 2-DG. However, when combined with metformin, inhibitor of mitochondrial respiration and activator of AMP-activated protein kinase, 2-DG synergistically enhanced ATP depletion and inhibited cell proliferation even in poorly glycolytic, 2-DG-resistant pancreatic cancer cell line. Furthermore, treatment with conventional chemotherapeutic drugs (e.g., gemcitabine and doxorubicin) or COX-2 inhibitor, celecoxib, sensitised the cells to 2-DG treatment.Conclusions:Detailed profiling of cellular bioenergetics can provide new insight into the design of therapeutic strategies for inhibiting pancreatic cancer cell metabolism and proliferation.",
keywords = "2-deoxyglucose, bioenergetics, cell proliferation, glycolysis, metformin, mitochondrial respiration, pancreatic cancer, targeted therapeutics",
author = "G. Cheng and J. Zielonka and D. McAllister and S. Tsai and Dwinell, {M. B.} and B. Kalyanaraman",
year = "2014",
doi = "10.1038/bjc.2014.272",
language = "English (US)",
volume = "111",
pages = "85--93",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Profiling and targeting of cellular bioenergetics

T2 - Inhibition of pancreatic cancer cell proliferation

AU - Cheng, G.

AU - Zielonka, J.

AU - McAllister, D.

AU - Tsai, S.

AU - Dwinell, M. B.

AU - Kalyanaraman, B.

PY - 2014

Y1 - 2014

N2 - Background:Targeting both mitochondrial bioenergetics and glycolysis pathway is an effective way to inhibit proliferation of tumour cells, including those that are resistant to conventional chemotherapeutics.Methods:In this study, using the Seahorse 96-well Extracellular Flux Analyzer, we mapped the two intrinsic cellular bioenergetic parameters, oxygen consumption rate and proton production rate in six different pancreatic cancer cell lines and determined their differential sensitivity to mitochondrial and glycolytic inhibitors.Results:There exists a very close relationship among intracellular bioenergetic parameters, depletion of ATP and anti-proliferative effects (inhibition of colony-forming ability) in pancreatic cancer cells derived from different genetic backgrounds treated with the glycolytic inhibitor, 2-deoxyglucose (2-DG). The most glycolytic pancreatic cancer cell line was exquisitely sensitive to 2-DG, whereas the least glycolytic pancreatic cancer cell was resistant to 2-DG. However, when combined with metformin, inhibitor of mitochondrial respiration and activator of AMP-activated protein kinase, 2-DG synergistically enhanced ATP depletion and inhibited cell proliferation even in poorly glycolytic, 2-DG-resistant pancreatic cancer cell line. Furthermore, treatment with conventional chemotherapeutic drugs (e.g., gemcitabine and doxorubicin) or COX-2 inhibitor, celecoxib, sensitised the cells to 2-DG treatment.Conclusions:Detailed profiling of cellular bioenergetics can provide new insight into the design of therapeutic strategies for inhibiting pancreatic cancer cell metabolism and proliferation.

AB - Background:Targeting both mitochondrial bioenergetics and glycolysis pathway is an effective way to inhibit proliferation of tumour cells, including those that are resistant to conventional chemotherapeutics.Methods:In this study, using the Seahorse 96-well Extracellular Flux Analyzer, we mapped the two intrinsic cellular bioenergetic parameters, oxygen consumption rate and proton production rate in six different pancreatic cancer cell lines and determined their differential sensitivity to mitochondrial and glycolytic inhibitors.Results:There exists a very close relationship among intracellular bioenergetic parameters, depletion of ATP and anti-proliferative effects (inhibition of colony-forming ability) in pancreatic cancer cells derived from different genetic backgrounds treated with the glycolytic inhibitor, 2-deoxyglucose (2-DG). The most glycolytic pancreatic cancer cell line was exquisitely sensitive to 2-DG, whereas the least glycolytic pancreatic cancer cell was resistant to 2-DG. However, when combined with metformin, inhibitor of mitochondrial respiration and activator of AMP-activated protein kinase, 2-DG synergistically enhanced ATP depletion and inhibited cell proliferation even in poorly glycolytic, 2-DG-resistant pancreatic cancer cell line. Furthermore, treatment with conventional chemotherapeutic drugs (e.g., gemcitabine and doxorubicin) or COX-2 inhibitor, celecoxib, sensitised the cells to 2-DG treatment.Conclusions:Detailed profiling of cellular bioenergetics can provide new insight into the design of therapeutic strategies for inhibiting pancreatic cancer cell metabolism and proliferation.

KW - 2-deoxyglucose

KW - bioenergetics

KW - cell proliferation

KW - glycolysis

KW - metformin

KW - mitochondrial respiration

KW - pancreatic cancer

KW - targeted therapeutics

UR - http://www.scopus.com/inward/record.url?scp=84904114424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904114424&partnerID=8YFLogxK

U2 - 10.1038/bjc.2014.272

DO - 10.1038/bjc.2014.272

M3 - Article

C2 - 24867695

AN - SCOPUS:84904114424

VL - 111

SP - 85

EP - 93

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 1

ER -